Table 4 Subsequent therapy after pembrolizumab or nivolumab progression
From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Category | Pembrolizumab (n = 25) | Nivolumab (n = 95) | P value |
|---|---|---|---|
Any post-nivolumab anti-cancer treatment | 10 (40.0%) | 40 (42.1%) | 0.85 |
Targeted therapy | Â | Â | Â |
 Lenvatinib | 2 (20.0%) | 11 (27.5%) |  |
 Sorafenib | 2 (20.0%) | 3 (7.5%) |  |
 Regorafenib | 0 (0%) | 6 (15.0%) |  |
 Ramucirumab | 3 (30.0%) | 5 (12.5%) |  |
 Cabozantinib | 1 (10.0%) | 4 (10.0%) |  |
 Thalidomide | 0 (0%) | 5 (12.5%) |  |
Chemotherapy | Â | Â | Â |
 FOLFOX | 1 (10.0%) | 12 (30.0%) |  |
 Epirubicin | 2 (20.0%) | 7 (17.5%) |  |
 Gemcitabine | 0 (0%) | 2 (5.0%) |  |
Immune checkpoint inhibitors | Â | Â | Â |
 Atezolizumab plus bevacizumab | 1 (10.0%) | 4 (10.0%) |  |
 Nivolumab plus ipilimumab | 2 (20.0%) | 1 (2.5%) |  |
 Pembrolizumab | 0 (0%) | 2 (5.0%) |  |
 Nivolumab | 2 (20.0%) | 0 (0%) |  |